{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-069133","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.581929+00:00","generated_at":"2026-06-04T16:40:41.675114+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BMS terminates ETB collaboration with Molecular Templates; termination effective June 13, 2024","bullets":["BMS notified Molecular Templates on March 13, 2024 of intent to terminate the Collaboration Agreement entered in February 2021.","Termination becomes effective June 13, 2024; company will reduce costs and focus resources on wholly-owned clinical-stage programs.","Collaboration leveraged Molecular Templates' ETB platform for novel products; BMS cited portfolio prioritization.","Molecular Templates will no longer receive research support from BMS under the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-069133","json":"https://secwatch.observer/filing/0001193125-24-069133.json","markdown":"https://secwatch.observer/filing/0001193125-24-069133.md","text":"https://secwatch.observer/filing/0001193125-24-069133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524069133/0001193125-24-069133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524069133/d813216d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T16:40:41.675114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a951b9db29677be7de8247a682957ce5590f3934","claim":"Molecular Templates, Inc. terminated Collaboration Agreement with Bristol Myers Squibb Company (effective 2024-06-13).","evidence_excerpt":"BMS notified the Company on March 13, 2024 that it does not intend to continue the research collaboration it entered into with the Company pursuant to the Collaboration Agreement and would be terminating the Collaboration Agreement in its entirety. The termination will be effective on June 13, 2024","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524069133/0001193125-24-069133-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Bristol Myers Squibb Company"},{"label":"Effective","value":"2024-06-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}